← Back to Clinical Trials
Recruiting NCT05184296

NCT05184296 ExtraCorporeal Membrane Oxygenation in the Therapy for REfractory Septic Shock With Cardiac Function Under Estimated

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05184296
Status Recruiting
Phase
Sponsor Second Affiliated Hospital of Guangzhou Medical University
Condition Extracorporeal Membrane Oxygenation
Study Type INTERVENTIONAL
Enrollment 64 participants
Start Date 2023-05-01
Primary Completion 2025-12-31

Trial Parameters

Condition Extracorporeal Membrane Oxygenation
Sponsor Second Affiliated Hospital of Guangzhou Medical University
Study Type INTERVENTIONAL
Phase N/A
Enrollment 64
Sex ALL
Min Age 18 Years
Max Age 75 Years
Start Date 2023-05-01
Completion 2025-12-31
Interventions
Extracorporeal Membrane Oxygenation (ECMO)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The ECMO-RESCUE study is a prospective, multicenter, non-randomized, cohort study. In this study, we aimed to assessed whether VA-ECMO treatment can improve the 30-day survival rate of patients with sepsis-induced refractory cardiogenic shock.

Eligibility Criteria

Inclusion Criteria: * Age between 18 and 75 years. * Patients admitted into ICU and diagnosed as septic shock (sepsis-3.0)13, after adequate fluid resuscitation, high-dose vasoactive drug application \[vasoactive inotropic score (VIS) \> 120\] and conventional therapy together with at least one of the following criteria: (1) sustained hypotension \[mean arterial pressure (MAP) \< 65 mmHg\]; (2) persistent lactacemia (two consecutive values \> 5 mmol/L with at least 30 min interval between samples), with non-decreasing trend on steady doses of inotropes and/or vasopressors; (3) persistent low mixed venous blood oxygen saturation (SvO2) (two consecutive values \< 55% with at least 30 min interval between samples), with non-increasing trend on steady doses of inotropes and/or vasopressors. The above condition lasts more than 5 hours. * Rapidly deteriorating sepsis-induced myocardial impairment is defined by at least one of the following criteria: (1) rapidly deteriorating ventricular func

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology